Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

Core Insights - Virax Biolabs Group Limited has initiated patient enrollment for a multi-center clinical study in the UK to assess the performance of its ViraxImmune™ FluoroSpot T cell assay in detecting T cell dysfunction in patients with post-acute infection syndromes, including long COVID and other related conditions [1][2][3] Group 1: Clinical Study Details - The clinical study, registered as NCT06731179, is conducted in collaboration with the UK's National Health Service and aims to enroll up to 200 participants [2] - Initial data from this longitudinal assessment is expected to be available in Q2 2026 [2] Group 2: Company Objectives and Potential - The CEO of Virax Biolabs emphasized the lack of reliable diagnostics for conditions associated with post-acute infection syndromes, stating that the study's data will enhance understanding of immune dysregulation and improve diagnostics and patient care [3] - The ViraxImmune™ assay is positioned to potentially improve immune health assessment, leading to earlier treatment interventions and better patient outcomes [3] Group 3: Company Overview - Virax Biolabs is focused on developing T cell-based test technologies aimed at providing an immunology profiling platform, particularly effective for diagnosing post-viral syndromes like Long COVID and chronic conditions linked to immune dysregulation [4]